About US
Contact us
-
Pfizer nabs extra time with blockbuster Celebrex patentThank you, U.S. patent office. Pfizer ($PFE) won an extra 18 months of exclusivity for its pain drug Celebrex, in the form of a reissued patent that doesn't expire till the end of 2015. That means a2013/3/6
-
GSK, Hospira litigation highlights danger in contract manufacturingContract manufacturing can solve all kinds of problems and save all kinds of money, but if things go bad it can bring on a world of hurt. When Boehringer Ingelheim's Ben Venue plant had to close down2013/3/6
-
Novartis pay furor swayed vote on Swiss restrictions, official saysThe Swiss have spoken on executive pay. In a national referendum, two-thirds of voters approved sweeping new restrictions. It was a thump on the head to companies that bestow increasingly lavish comp2013/3/5
-
India sinks Bayer's hopes on Nexavar patentIt is a not-so-happy anniversary for Germany's Bayer AG. A year after the company became the first to have a drug targeted by India's compulsory licensing law, an appeals board has said there will be2013/3/5
-
Roche dropping Herceptin price in India by 30%Roche, whose patents have been under attack in India, is moving forward with plans to manufacture some drugs in the country, indicating it will drop the prices by as much as 50%, even as it faces a ne2013/3/4
-
Roche and Hamilton Introduce New Automated DNA Sample Enrichment Platform for GS Junior Sequencing InstrumentsToday Roche and Hamilton Robotics jointly announced the introduction of a new, integrated platform enabling automated DNA sample enrichment for Roche’s 454 GS Juniorsequencer. The platform builds on2013/3/4
-
Sartorius Stedim Biotech Expands PAT Portfolio by Adding Sensor Technology for Real-Time Biomass MeasurementSartorius Stedim Biotech (SSB), a leading international supplier for the pharmaceutical and biotech industries, has entered into a global sales anddevelopment partnership with Aber Instruments (Aber)2013/3/1
-
Bayer bucks pharma trend with 'remarkable' growth in new drugsBayer's new drugs are bringing home the bacon. The German drugmaker raised its 2015 forecast for 5 key products to €2.5 billion ($3.3 billion)--and confirmed previous promises that those drugs would2013/3/1
-
Hospira issues 3 recalls as it faces crucial FDA inspectionSterile injectables maker Hospira ($HSP) is having to recall lots of 5 different products even as FDA inspectors are in one of its plants conducting what the company hopes will be a final inspection2013/2/28
-
Amgen loses Supreme Court ruling in shareholder suitAmgen just can't escape the spotlight. The biotech company was accused last month of getting special favors from lawmakers. Today the U.S. Supreme Court ruled against it in a securities case that set2013/2/28